PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16979119-6	2006	Clinically relevant concentrations of fenretinide (1.25, 2.5 and 5 microM) inhibited TNF-alpha-induced IL-8 production of CF cells by up to 73% but had no effect or increased the IL-8 production in non-CF cells.	Fenretinide	38-49	C-X-C motif chemokine ligand 8	Homo sapiens	103-107	
16979119-7	2006	Although fenretinide treatment was associated with a higher intracellular ceramide content in the mutant DeltaF508 CFTR cells, the fenretinide-mediated decrease in IL-8 secretion was not consistently explained by changes in the intracellular content of this sphingolipid.	Fenretinide	131-142	C-X-C motif chemokine ligand 8	Homo sapiens	164-168	
16979119-9	2006	The fenretinide mediated decrease in IL-8 release in CF cells under TNF-alpha stimulated conditions presents the possibility that the lung inflammation in CF could be attenuated via low dose fenretinide treatment.	Fenretinide	4-15	C-X-C motif chemokine ligand 8	Homo sapiens	37-41	
16979119-9	2006	The fenretinide mediated decrease in IL-8 release in CF cells under TNF-alpha stimulated conditions presents the possibility that the lung inflammation in CF could be attenuated via low dose fenretinide treatment.	Fenretinide	191-202	C-X-C motif chemokine ligand 8	Homo sapiens	37-41	
16979119-0	2006	Inhibition of IL-8 release from CFTR-deficient lung epithelial cells following pre-treatment with fenretinide.	Fenretinide	98-109	C-X-C motif chemokine ligand 8	Homo sapiens	14-18	
31515297-11	2019	Notably, combination fenretinide-tocilizumab-reparixin treatment significantly suppressed IL-6 and IL-8 release, stem cell gene expression, and invasion in these diverse CSCE populations.	Fenretinide	21-32	C-X-C motif chemokine ligand 8	Homo sapiens	99-103